**Author details**

Recep Öztürk Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey

\*Address all correspondence to: ozturk\_recep@windowslive.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**95**

*Current Therapeutic Approaches for Osteosarcoma DOI: http://dx.doi.org/10.5772/intechopen.98434*

osteosarcoma of the extremity. Updated

results of the Multi-Institutional Osteosarcoma Study. Clin OrthopRelat

[10] Bloem JL, Kroon HM. Osseous lesions. Radiol Clin North Am 1993;

[11] Ozturk R, Bone and Soft Tissue Tumors. In: Atay T, ed. Orthopedics and Sport Medicine Guide for Researchers. Ankara; DermanMedical Publishing; 2015:635-704. DOİ: 10.4328/DERMAN.

[12] Yamaguchi H, Minami A, Kaneda K, Isu K, Yamawaki S. Comparison of magnetic resonance imaging and computed tomography in the local assessment of osteosarcoma. Int Orthop.

1992;16(3):285-90. DOİ: 10.1007/

[13] Mankin Hj, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors. J Bone and Joint Surg Am

[14] Hız M. Osteosarcoma, malignant fibrous histiocytoma – clinical radiology, pathology and treatment strategies. TOTBİ DDergisi 2014; 13:227-239 DOİ: 10.14292/totbid.

[15] Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer. 1999;86(8):1602-8. DOİ: 10.1002/(sici)1097-0142

(19991015)86:8<1602::aid-cncr31>3.0.

[16] Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment where do we stand? A state of the art

review. Cancer Treat Rev.

Res. 1991;(270):8-14.

31: 61-78.

3774.

BF00182713.

1982;64:1121-1127

dergisi.2014.25.

co;2-r.

[1] Whelan JS. Osteosarcoma. Eur J Cancer. 1997;33(10):1611-1618; discussion 1618-9. DOI: 10.1016/

[2] Mirra JM. Malignant Bone Tumours. In: Mirra JM, Picci P, Gold RH. Bone Tumours: Clinical, Radiologic, and Pathologic Correlations, Philadelphia: Lea and Febiger; 1989. p.248-389.

[3] Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009 Jul;125(1):229-234. DOI:

[4] Öztürk R, İnce B, Karakoç Y,

Evaluation of Demographic and Clinicopathological Characteristics of Osteosarcoma Patients. Acta Oncol Tur. 2019;52(2):266-270. DOI: 10.5505/

Arıkan ŞM, Yapar AE, Erdoğdu Yİ, et al.

[5] Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin OrthopRelat Res. 2002;(397):40-52. DOI: 10.1097/ 00003086-200204000-00007.

[6] Mirabello L, Yeager M, Mai PL, Gastier-Foster JM, Gorlick R, Khanna C, et al.. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst. 2015;107(7):djv101. DOI:

[7] Greanspan A, Jundt G, Remagen W. Differential Diagnosis in Orthopaedic Oncology. Bone Forming (Osteogenic)

[8] Greenspan A. Orthopedic Imaging.

[9] Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade

Lesions. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;

4th ed. California, Lippincott Williams& Wilkins. 2005; 689-696.

s0959-8049(97)00251-7.

10.1002/ijc.24320.

aot.2019.60234.

10.1093/jnci/djv101.

2007. p.88-9.

**References**

*Current Therapeutic Approaches for Osteosarcoma DOI: http://dx.doi.org/10.5772/intechopen.98434*
